New Kidney Transplant Drug Could Better Preserve Function
A new drug may offer first-time transplant recipients better kidney function and quality of life than current standards.
Updated on Oct. 24, 2026 in Stroke
Live Poll
Are you confident that new medical therapies will successfully reduce side effects from current long-term treatments?
A Phase 2 clinical trial shows that the investigational drug tegoprubart better preserves kidney function in first-time transplant recipients compared to the current standard, tacrolimus. Patients receiving the new therapy also reported improvements in quality of life metrics at 52 weeks.
Why it matters
Tacrolimus is a standard immunosuppressant used after transplants, but it can be associated with side effects that impact kidney function over time. Findings from the BESTOW trial suggest a potential new pathway for managing transplant patients that could improve long-term graft health.
In a Phase 2 trial of 127 patients, tegoprubart demonstrated a statistically significant kidney function benefit at 18 months compared to tacrolimus. While results are promising, the long-term clinical safety profile beyond this study period remains under investigation.
The players
University of Minnesota Medical School
An academic institution whose researchers led the investigation into new transplant immunosuppression strategies.
The details
Tegoprubart works by targeting the CD40L pathway to manage the immune system's response to a new organ. By inhibiting this specific pathway, the drug helps stabilize kidney graft function after the initial month of treatment. Patients in the study also saw improvements across all five measured subscales of health-related quality of life, whereas those on tacrolimus saw improvements in four.
Timeline
October 22-25, 2026: Findings presented at ASN Kidney Week 2026.
Week 52: Assessment point for health-related quality of life.
18 months: Timeframe for measured statistical significance of kidney function benefit.
Health Landscape
The standard approach to preventing organ rejection has long relied on tacrolimus, but it presents ongoing challenges for long-term patient and graft health. The emergence of CD40L-targeting therapies like tegoprubart represents a new direction in the evolution of transplant medicine.
Patients who have undergone or are planning a kidney transplant should discuss the potential for new immunosuppression therapies with their transplant team. It is essential to monitor how current medication regimens affect your specific graft function and overall quality of life.
The takeaway
While these findings are early-stage, they represent an important advancement in the pursuit of more effective organ preservation strategies. Patients should maintain open communication with their physicians regarding any new research or emerging treatment options relevant to their transplant care.
Further reading
For more information on managing kidney health and transplant recovery, visit our Stroke section.
Live Poll
Are you confident that new medical therapies will successfully reduce side effects from current long-term treatments?
